Patents by Inventor Pascal Druzgala

Pascal Druzgala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6686377
    Abstract: The subject invention concerns novel analogs of fentanyl opioids. The subject invention also concerns methods for synthesizing the compounds of the invention. The invention also concerns methods for treating pain in a patient by administering a compound of the invention to a person in need of such treatment.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: February 3, 2004
    Assignee: ARYx Therapeutics
    Inventor: Pascal Druzgala
  • Patent number: 6683195
    Abstract: The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The enantiomerically purified compounds, and compositions of these compounds, exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats, as compared to racemic mixtures of the compounds.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: January 27, 2004
    Assignee: ARYx Therapeutics
    Inventors: Pascal Druzgala, Peter G. Milner
  • Patent number: 6683086
    Abstract: The subject invention concerns novel compounds that are useful as ultrashort acting hypnotic barbiturates. Specifically exemplified are derivatives of barbituric and thiobarbituric acids. They are rapidly metabolized by blood and tissue enzymes to form polar metabolites with no hypnotic activity and which are rapidly eliminated.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: January 27, 2004
    Assignee: ARYx Therapeutics
    Inventors: Pascal Druzgala, Peter G. Milner
  • Patent number: 6680387
    Abstract: The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: January 20, 2004
    Assignee: ARYx Therapeutics
    Inventors: Pascal Druzgala, Peter G. Milner, Jurg R. Pfister
  • Publication number: 20030236227
    Abstract: The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.
    Type: Application
    Filed: September 20, 2002
    Publication date: December 25, 2003
    Inventors: Pascal Druzgala, Peter G. Milner, Jurg R. Pfister
  • Publication number: 20030216387
    Abstract: The subject invention provides novel compounds and compositions for the safe and effective treatment of gastroesophageal reflux and related conditions. In a preferred embodiment, the compositions of the subject invention comprise esterified cisapride derivatives. These compositions possess potent activity in treating gastroesophageal reflux disease and substantially reduce adverse effects associated with the administration of cisapride. These adverse effects include, but are not limited to, diarrhea, abdominal cramping and elevations of blood pressure and heart rate.
    Type: Application
    Filed: April 18, 2003
    Publication date: November 20, 2003
    Inventors: Pascal Druzgala, Peter G. Milner, Jurg Pfister, Cyrus Becker
  • Publication number: 20030199573
    Abstract: This invention is drawn to compounds which are more easily metabolized by the metabolic drug detoxification systems. Particularly, warfarin analogs which have been designed to include esters within the structure of the compounds are taught. The invention teaches methods of reducing the toxicity of drugs comprising the introduction of ester groups into drugs during the synthesis of the drug. This invention is also drawn to methods of treating coagulation disorders comprising the administration of compounds which have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester containing warfarin, analogs are also taught.
    Type: Application
    Filed: April 24, 2002
    Publication date: October 23, 2003
    Inventors: Pascal Druzgala, Xiaoming Zhang, Jurg Pfister
  • Publication number: 20030158194
    Abstract: The subject invention pertains to novel compounds (and salts thereof), and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. This results in an improved safety profile. The new compounds have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The compounds also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.
    Type: Application
    Filed: December 10, 2002
    Publication date: August 21, 2003
    Inventor: Pascal Druzgala
  • Publication number: 20030158221
    Abstract: The subject invention provides useful and novel 5-HT3 antagonists. The subject invention also provides methods for synthesizing the compounds of invention. The invention also provides methods for the treatment of irritable bowel syndrome and other such conditions.
    Type: Application
    Filed: January 21, 2003
    Publication date: August 21, 2003
    Inventors: Xiaming Zhang, Jurg R. Pfister, Cyrus Becker, Pascal Druzgala
  • Patent number: 6608097
    Abstract: The subject invention provides useful and novel calcium channel blockers based upon mibefradil. The subject invention also provides methods for synthesizing the compounds of the invention. The invention also provides methods for the control or prevention of hypertension, angina pectoris, ischemia, arrhythmias, and cardiac insufficiency in a patient by administering a compound, or composition, of the invention to an individual in need of such treatment.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: August 19, 2003
    Assignee: ARYx Therapeutics
    Inventors: Pascal Druzgala, Peter G. Milner, Jürg Pfister, Xiaoming Zhang
  • Publication number: 20030130330
    Abstract: The subject invention provides useful and novel calcium channel blockers based upon mibefradil. The subject invention also provides methods for synthesizing the compounds of the invention. The invention also provides methods for the control or prevention of hypertension, angina pectoris, ischemia, arrhythmias, and cardiac insufficiency in a patient by administering a compound, or composition, of the invention to an individual in need of such treatment.
    Type: Application
    Filed: October 10, 2002
    Publication date: July 10, 2003
    Inventors: Pascal Druzgala, Peter G. Milner, Jurg Pfister, Xiaoming Zhang
  • Publication number: 20030130314
    Abstract: Novel and advantageous delivery systems for the delivery of analgesic compounds and compositions to patients who are suffering from intractable pain are provided. In some embodiments, these patients already are under the background influence of an opioid agonist. The subject invention also provides methods of managing pain comprising the administration of analgesic compounds via transdermal or transmucosal delivery routes.
    Type: Application
    Filed: December 17, 2002
    Publication date: July 10, 2003
    Inventor: Pascal Druzgala
  • Publication number: 20030100575
    Abstract: The subject invention concerns novel compounds that are useful as ultrashort acting hypnotic barbiturates. Specifically exemplified are derivatives of barbituric and thiobarbituric acids. They are rapidly metabolized by blood and tissue enzymes to form polar metabolites with no hypnotic activity and which are rapidly eliminated.
    Type: Application
    Filed: May 13, 2002
    Publication date: May 29, 2003
    Inventors: Pascal Druzgala, Peter G. Milner
  • Publication number: 20030078284
    Abstract: The subject invention provides compounds which are easily metabolized by the metobolic drug detoxification systems. Particularly, fluvoxamine analogs which have been designed to include esters within the structure of the compounds are taught. Also provided are methods of treating depression and affective disorders, such as obsessive compulsive disorder. Pharmaceutical compositions of the fluvoxamine analogs are also taught.
    Type: Application
    Filed: October 18, 2002
    Publication date: April 24, 2003
    Inventor: Pascal Druzgala
  • Patent number: 6552046
    Abstract: The subject invention provides novel compounds and compositions for the safe and effective treatment of gastroesophageal reflux and related conditions. In a preferred embodiment, the compositions of the subject invention comprise esterified cisapride derivatives. These compositions possess potent activity in treating gastroesophageal reflux disease and substantially reduce adverse effects associated with the administration of cisapride. These adverse effects include, but are not limited to, diarrhea, abdominal cramping and elevations of blood pressure and heart rate.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: April 22, 2003
    Assignee: Aryx Therapeutics
    Inventors: Pascal Druzgala, Peter G. Milner, Jürg Pfister, Cyrus Becker
  • Publication number: 20030064972
    Abstract: The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.
    Type: Application
    Filed: April 24, 2001
    Publication date: April 3, 2003
    Inventors: Pascal Druzgala, Peter G. Milner, Jurg R. Pfister
  • Publication number: 20030054974
    Abstract: The subject invention provides therapeutically useful and therapeutically effective compounds and compositions for the treatment of a variety of disorders. The compounds of the invention exhibit significantly reduced levels of drug-drug interactions (DDI) and are metabolized, primarily, via non-oxidative systems.
    Type: Application
    Filed: August 26, 2002
    Publication date: March 20, 2003
    Applicant: Aryx Therapeutics
    Inventor: Pascal Druzgala
  • Publication number: 20030027798
    Abstract: The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.
    Type: Application
    Filed: September 21, 2001
    Publication date: February 6, 2003
    Inventors: Pascal Druzgala, Peter G. Milner, Jurg R. Pfister
  • Publication number: 20020193428
    Abstract: The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The enantiomerically purified compounds, and compositions of these compounds, exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats, as compared to racemic mixtures of the compounds.
    Type: Application
    Filed: April 15, 2002
    Publication date: December 19, 2002
    Inventors: Pascal Druzgala, Peter G. Milner
  • Publication number: 20020183343
    Abstract: The subject invention concerns novel analogs of fentanyl opioids. The subject invention also concerns methods for synthesizing the compounds of the invention. The invention also concerns methods for treating pain in a patient by administering a compound of the invention to a person in need of such treatment.
    Type: Application
    Filed: April 3, 2002
    Publication date: December 5, 2002
    Inventor: Pascal Druzgala